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Abstract
Highly homologous B-cell receptors, characterized by non-random combinations of immunoglobulin heavy-chain variable
(IGHV) genes and heavy-chain complementarity determining region-3 (HCDR3), are expressed in a recurrent fraction of
patients affected by chronic lymphocytic leukemia (CLL). We investigated the IGHV status of 1131 productive IG
rearrangements from a panel of 1126 CLL patients from a multicenter Italian study group, and correlated the presence and
class of HCDR3 stereotyped subsets with the major cytogenetic alterations evaluated by FISH, molecular prognostic factors,
and the time to first treatment (TTFT) of patients with early stage disease (Binet A). Stereotyped HCDR3 sequences were
found in 357 cases (31.7%), 231 of which (64.7%) were unmutated. In addition to the previously described subsets, 31 new
putative stereotypes subsets were identified. Significant associations between different stereotyped HCDR3 sequences and
molecular prognostic factors, such as CD38 and ZAP-70 expression, IGHV mutational status and genomic abnormalities were
found. In particular, deletion of 17p13 was significantly represented in stereotype subset #1. Notably, subset #1 was
significantly correlated with a substantially reduced TTFT compared to other CLL groups showing unmutated IGHV, ZAP-70
or CD38 positivity and unfavorable cytogenetic lesions including del(17)(p13). Moreover, subset #2 was strongly associated
with deletion of 13q14, subsets #8 and #10 with trisomy 12, whereas subset #4 was characterized by the prevalent
absence of the common cytogenetic abnormalities. Our data from a large and representative panel of CLL patients indicate
that particular stereotyped HCDR3 sequences are associated with specific cytogenetic lesions and a distinct clinical
outcome.
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Introduction
Chronic lymphocytic leukemia (CLL) is a common disorder
characterized by the monoclonal accumulation of B lymphocytes
with a distinct phenotype (CD5-positive, CD23-positive, CD22-
negative and low level of surface Ig) and a highly variable clinical
course [1–3]. A different clinical outcome has been associated with
peculiar cellular and molecular markers and/or specific genomic
alterations [4–6]. In particular, the mutational status of the
immunoglobulin heavy-chain variable (IGHV) gene defines two
disease subgroups; one subgroup is characterized by the absence of
somatic mutation in CLL cells and has the worst clinical course
and outcome, whereas the other, with somatic mutations in IGHV
genes, has a more benign prognosis and outcome [7,8]. A biased
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reported to characterize the B cell receptor (BCR) in CLL, with a
different prevalence of certain genes in the mutated (M) or
unmutated (UM) group, respectively [9]. Moreover, more than
20% of CLL patients exhibit closely homologous (‘‘stereotyped’’)
heavy chain complementary-determining region 3 (HCDR3)
sequences and approximately 1% of these also carry virtually
identical IGHV amino-acid sequences [10–13]. These findings
have suggested that clones sharing stereotyped BCRs may expand
because of stimulation by a restricted set of epitopes and that
antigenic driving may play an important role in the pathogenesis
of the disease [6,14–16].
Although recent data have suggested the existence of specific
correlation between stereotyped subsets and common cytogenetic
lesions [17,18] or clinical outcome [10,13,19,20], it remains to be
defined whether the expression of distinct BCRs in CLL may be
relevant to the molecular and cytogenetic profile and/or to the
clinical outcome in at least a fraction of patients.
In the present study, we investigated the BCR repertoire in
1126 CLL patients recruited by a multicenter Italian study group.
Based on previously reported criteria [10,21] and canonical
sequence alignment procedures, we searched for the known
stereotyped subsets in three publicly available data sets [10,22,23],
as well as for potential novel subsets by performing a pair-wise
alignment in the proprietary dataset. The most represented
stereotyped subsets were then investigated for their association
with the common molecular and cytogenetic features as well as for
their impact on clinical outcome of early stage patients (Binet A).
Methods
Patient samples
Written informed consent was obtained from all patients in
accordance with the declaration of Helsinki and the study was
approved by the local Ethics Review Committee (Comitato Etico
Provinciale, Modena, Italy). All patients were diagnosed according
to the National Cancer Institute Working Group criteria [24]. Our
dataset counted a total of 1126 CLL patients with productive
IGHV-D-J rearrangement included in retrospective (745 patients)
and prospective (381 patients, O-CLL1-GISL protocol) multicen-
ter Italian studies from all over the country. In all cases genomic,
cytogenetic and molecular analyses were performed on highly
purified peripheral mononuclear B-cells from blood samples
collected within one year of diagnosis, provided that the patient
remained untreated.
Molecular and FISH analyses
CLL IGHV gene usage and mutation were determined as
previously described and the 98% homology cut-off value was used
to discriminate the M or UM IGHV configuration [9]. ZAP-70 and
CD38 expression were investigated by immunophenotypic analysis
as previously described [25–27]. Specifically, a cut-off $20% or
$30% positive cells was chosen to discriminate ZAP-70 or CD38
positive from negative patients. Cytogenetic abnormalities involv-
ing deletions at chromosomes 11q23, 13q14 and 17p13 and
trisomy of chromosome 12 were investigated by fluorescence in
situ hybridization (FISH) as previously described [28]. FISH
analyses were performed in all of the patients for whom biological
material was available, and no prior selection based on age or
disease progression was applied. Time to First Treatment (TTFT)
was defined as time from diagnosis to first line treatment (event) or
to last follow-up (censored observation). Treatment was decided
uniformly in all participating centers based on documented
progressive and symptomatic disease according to NCI working
guidelines [24]. TTFT information was available for 739 patients
(661 staged as Binet A; 56 as Binet B and 22 as Binet C), median
follow up was 30 months (range 1–316 months), and 237 (32.1%)
patients had received treatment by the end of the follow up.
Identification of stereotyped subsets and statistical
analysis
We assigned a stereotyped cluster label to our HCDR3
sequences by means of pair-wise alignment with known stereo-
typed sequences available from different public databases
[10,22,23]. In concordance with previously proposed methods,
we applied a primary filter excluding pairs of sequences whose
length differed more than 3 amino acids and we considered as
stereotyped those sequences sharing more than 60% identity on
alignments showing less than 3 gaps [10,29]. Such analysis was
performed using a global alignment algorithm [30] with BLOSUM62
as the similarity matrix [31] under the BioStrings package for
Bioconductor. The same approach was applied to discover new
potential stereotyped clusters with pair-wise alignments of the
sequences from the proprietary database. A supplemental ‘‘GX’’
number was assigned to novel putative subsets not previously
included in the Murray et al and Bomben et al nomenclature
system [22,23]. All contingency analyses were performed by
Fisher’s Exact test. The competing effect of death on the
relationship between TTFT and stereotyped BCRs was modeled
by proportional hazards of competing risks. Correlation with
TTFT was tested between the considered groups in Binet A
patients using the crr function of cmprsk package in R software [32].
A P value ,0.05 was considered significant for all statistical
calculations. All data were statistically analyzed using conventional
procedures available in R (www.r-project.org).
Results
A total of 1126 CLL patients were investigated for productive
IGHV-D-J rearranged sequences; 5 patients carried a double in
frame productive rearrangement. Based on the 98% homology
criteria, 405/1126 patients (36%) were classified as UM (Table 1
and Figure S1). IGHV, IGHD and IGHJ gene type and distribution
are reported in Figure S2A–C [10,22,23]. ZAP-70 and CD38
expression were positive in 367/1011 (36.3%) and 306/1051
(29.1%%) of cases, respectively. Interphase FISH was performed
on 704 patients and at least one abnormality was found in 466/
704 (66.2%) of cases. Based on proposed hierarchical classification
[4–6], del(13)(q14) was found as the sole abnormality in 287/704
(40.7%); trisomy 12 was found in 98/704 (13.9%) patients and
associated with del(13)(q14) in 9 cases; del(11)(q23) was found in
46/704 (6.5%) patients and associated with del(13)(q14) and
trisomy 12 in 25 and 1 cases, respectively; del(17)(p13) was found
in 35/704 (5%) patients and associated in 5 and in 1 cases with
del(13)(q14) and trisomy 12, respectively.
Identification of stereotyped sequences
To identify stereotyped HCDR3 sequences occurring in our
dataset, we performed a global alignment analysis which allowed
(a) to compare each of our cases with publicly available data
[10,22,23] and (b) to investigate the occurrence of new putative
stereotypes within the proprietary database. Using this approach,
stereotyped sequences were found in 357/1126 (31.7%) of the
patients, 64.7% (231/357) of which were UM (P,0.0001), further
supporting previous evidence [10,22,23].
Among patients with stereotyped HCDR3, 294 (82.3%)
belonged to previously described subsets. In particular, the most
recurrent subsets identified in our study were #1 (32 pts), #4 (29
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S1). Of note, the global alignment procedures performed on pair-
wise sequences of our dataset allowed the identification of 31 new
putative subsets in 63 patients (63/357;17.7%) recorded with a
progressive code from G1 to G31 (see Table S2).
Correlation between cellular and molecular features with
stereotyped BCRs in CLL
We then evaluated the prevalence of known molecular,
biological and cytogenetic markers in the most represented and
characterized stereotyped subsets of our dataset (Table 2). Subset
#1( IGHV1-5-7/IGHD6-19/IGHJ4) was the most frequent in our
cohort. Despite the relatively heterogeneous gene usage, it was
associated with UM IGHV genes in all of the cases (32pts). Subset
#1 patients were more frequently ZAP-70 and CD38 positive
compared to all the other patients (P,0.0001) or those utilizing
the same IGHV genes without stereotyped HCDR3 (P=0.0002 and
P,0.0001 for ZAP-70 and CD38, respectively). However, no
significant association between subset #1 and ZAP-70/CD38
positivity was identified when compared to patients with the UM
IGHV configuration (data not shown). Considering only patients
(18/32;56.3%) evaluated by FISH, we observed a higher
prevalence of unfavorable deletions (7/18; 38.9%), particularly
del(17)(p13) (5/18; 27.8%) (Table 2). Notably, the prevalence of
del(17p)(p13) in subset #1 patients was significantly higher than
that found in all the remaining patients (30/686;4.3%)
(P=0.0012). To avoid that the prevalent UM status in subset
#1 may represent a bias factor, we compared the frequency of
del(17)(p13) between subset #1 and all the remaining UM patients
(22/244; 9%) confirming the previous association (P=0.0266).
Furthermore, comparing subset #1 patients with those showing
the same IGHV gene usage without homologous HCDR3,w e
observed that del(17)(p13) retained its significant correlation
(P=0.0064). The percentage (median 78%: range 33.5–99) of
malignant cells carrying the del(17)(p13) in subset #1 patients did
not differ significantly in the remaining ones (30pts) having the
del(17)(p13) (data not shown).
A number of additional correlations between distinct stereo-
typed HCDR3 and cytogenetic/molecular features were evidenced
in our panel. The cytogenetic profile of subset #2( IGHV3-21) was
characterized by a very strong prevalence of del(13)(q14) (12/13;
92.3%), found as the sole abnormality in 10 patients and
associated with the del(11)(q23) in the remaining two (Table 2).
When compared to the whole panel (313/684; 45.7%), this finding
was statistically significant (P=0.0009). Of note, differently from
another group [13] we did not observe any significant difference
between patients admitted to Institutions from North or South
Italy in terms of IGHV3-21 usage (20/548 and 14/578
Table 1. Biological, molecular and cytogenetic features of CLL patients included in the study.
Variable N6 of positive/investigated patients (%) Correlation with TTFT
ZAP-70 367/1011 (36.3%) P,0.0001
CD38 306/1051 (29.1%) P,0.0001
IGHV* 405/1126 (36%) P,0.0001
No FISH alteration** 238/704 (33.8%) P,0.0001
Del(13)(q14) 287/704 (40.7%)
Trisomy 12 98/704 (13.9%)
Del(11)(q23) 46/704 (6.5%)
Del(17)(p13) 35/704 (5%)
* the number of investigated sequences was 1131 (see text).
** FISH results according to the hierarchical classification [4–6].
doi:10.1371/journal.pone.0024313.t001
Table 2. The molecular, cytogenetic and clinical characterization of the most representative and described subsets.
Subset N6 of pts Binet A* UM CD38 ZAP-70 FISH-neg del(13) 12 del(11)
del(11) and
del(13) del(17)
del(17) and
del(13)
#1 32 13 32/32 21/32 22/30 4/18 2/18 5/18 2/18 0/18 3/18 2/18
#2 20 12 10/20 3/17 5/15 1/13 10/13 0/13 0/13 2/13 0/13 0/13
#3 16 8 16/16 6/14 10/13 6/11 0/11 3/11 0/11 0/11 2/11 0/11
#4 29 19 1/29 0/25 3/24 13/23 9/23 1/23 0/23 0/23 0/23 0/23
#5 5 2 5/5 3/4 2/4 0/2 0/2 1/2 0/2 1/2 0/2 0/2
#6 5 2 5/5 3/3 1/3 2/4 1/4 0/4 0/4 0/4 1/4 0/4
#7 22 10 22/22 12/21 16/21 4/13 4/13 1/13 2/13 2/13 0/13 0/13
#8 8 5 8/8 6/7 7/7 1/7 0/7 5/7 0/7 0/7 1/7 0/7
#9 15 7 15/15 6/14 6/10 1/9 2/9 2/9 2/9 1/9 1/9 0/9
#10 11 5 10/10 8/10 10/10 1/7 0/7 6/7 0/7 0/7 0/7 0/7
*Patients in Binet A with complete follow-up.
doi:10.1371/journal.pone.0024313.t002
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(Table S3).
Subset #4( IGHV4-34) was characterized by an almost complete
M IGHV configuration and negative ZAP-70/CD38 expression
(Table 2). In addition, we found that subset #4 patients were
characterized by a low incidence of genomic aberrations. In fact,
among the 23 cases investigated by FISH, 13 (56.5%) were
negative for the most common cytogenetic lesions; this finding was
statistically significant when compared to all patients (225/681;
P=0.02) or those with M IGHV configuration (142/420;
Figure 1. TTFT analysis of subset #1. A: Subset #1 patients compared with all UM and M patients. B: Subset #1 compared with all non-
stereotyped UM and non-stereotyped M patients. C: Subset #1 compared with all UM and M patients showing the same IGHV usage of subset #1. D
and E: Subset #1 patients compared with the remaining cases grouped according to ZAP-70 and CD38 expression positivity, respectively.
doi:10.1371/journal.pone.0024313.g001
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#8( IGHV4-39/IGHD6-13/IGHJ5) (5/7; 71.4%) and subset #10
(IGHV4-39 and IGHV2-5/IGHD2-2/IGHJ6) (6/7; 85.7%), con-
firming its higher prevalence in IGHV4-39 stereotyped patients
[17,20]. Specifically, trisomy 12 was significantly associated with
subset #8 and #10 either when all patients or only those with UM
IGHV configuration were considered (data not showed). Finally,
subsets #8 and #10 were strongly associated with ZAP-70
positivity when all patients were considered (P=0.0008 and
P,0.0001 respectively). Instead, only subset #10 retained its
significant association with ZAP-70 considering only UM patients
(P=0.017). Moreover, a significant association between subset #8
and #10 and CD38 positivity was found when compared to all
patients (P=0.003 and P=0.0013 respectively), but not to UM
patients.
Clinical relevance of stereotyped subsets
We investigated whether the stereotype configuration was
correlated with disease progression. For this purpose only Binet
A patients were considered. Subset #1 (13 patients, see Table 2)
exhibited a significantly reduced TTFT when compared to all UM
patients (P,0.0001), UM non-stereotyped patients (P,0.0001), or
UM patients with the same IGHV gene usage (P,0.0001)
(Figure 1A–C). Additionally, subset #1 was associated with an
increased risk of earlier treatment compared to the presence of
ZAP-70 and CD38 positivity (P,0.0001) (Figure 1D–E). The
clinical course of subset #1 patients appeared to be similar to that
of patients with del(17p) or del(11q) (Figure 2). A multivariate
analysis using a proportional hazard model showed that subset #1
retained independence (P=0.0132) from del(17p), del(11q), IGHV
configuration and ZAP-70 or CD38 positivity. Moreover,
considering only UM patients, the prognostic power of subset
#1 maintained its significant independence from ZAP-70,
del(17p), del(11q) and CD38 (P=0.0102).
In agreement with previous reports [13,19,22], subset #2
(IGHV3-21) stereotyped patients had an unfavorable clinical
course compared to all other patients (P=0.00033) or to those
utilizing non-stereotyped IGHV3-21 sequences (P=0.052). In
addition, subset #2 did not show a more unfavorable clinical
course compared to UM patients (P.0.05).
Patients in subset #4 were characterized by a long TTT. In
fact, only 2/19 patients in Binet A had been treated at the time of
the study: of these, one was highly positive for ZAP-70 and the
other was the only one with UM IGHV configuration.
Finally, likely due to the low number of cases in our series, we
were unable to confirm the previously described [10] favorable or
unfavorable clinical outcome of subset #5( IGHV1-69/IGHD3-10/
IGHJ6) or subset #3( IGHV1-69/IGHD2-2/IGHJ6), respectively.
Discussion
In order to contribute to the elucidation of HCDR3 stereotyping
in CLL, we characterized the BCR repertoire in a comprehensive
panel of 1126 patients with the following aims: (a) to investigate
whether HCDR3 stereotyped sequences might be correlated with
molecular and cytogenetic profiles; and (b) to evaluate the putative
clinical relevance in terms of TTFT for the most represented
stereotypes.
In our study, we identified a total of 31.7% stereotyped HCDR3
sequences using an amino acid sequence alignment approach
according to previously reported criteria [10]. This percentage was
slightly higher than those reported to date [10,22,23], a finding in
all likelihood related to the assessment of proprietary database
stereotypes against previously reported ones. In fact, limiting the
analysis only to patients included in our cohort, the percentage
decreased to 28.3%, as 31 novel putative stereotyped sequences
were identified after comparison with the published registries.
Therefore, such a procedure (auto-matching and matching with
published data) may represent an optimal and unbiased approach
to perform stereotyped BCR characterization in CLL.
Our study revealed that subset #1, known to be the most
frequent (9% of all stereotyped cases and 7.9% of all UM patients
in our series) and characterized by UM IGHV configurations, was
significantly associated with del(17)(p13). Notably, subset #1
exhibited a more unfavorable clinical course than other patients
with an UM IGHV configuration, independently of the presence of
other adverse prognostic factors, such as del(17)(p13), del(11)(q23),
ZAP-70 and CD38 positivity or the usage of IGHV genes. The
finding that subset #1 shows the worst clinical outcome as found
in patients exhibiting 11q23 or 17p13 deletion suggests that it
might represent a reliable marker for high risk CLLs in the early
stage of the disease.
As regards subset #2( IGHV3-21), we confirmed its more
unfavorable clinical outcome. However, differently from previously
reported data [13], we did not observe a significant difference in the
geographical distribution of IGHV3-21 across Italy in our cohort of
patients. Moreover, we found the presence of del(13)(q14) in
virtually all patients tested by FISH (12/13); this finding is in
accordance with data recently published by Marincevic et al [18],
suggesting that this association could be considered subset-specific.I n
addition, we did not observe a strong association between
del(11)(q23) and subset #2 as described by the same authors [18].
This discrepancy could be partially explained by the lower number
of subset #2 patients analyzed by FISH in our study. However, it
should be noted that all but one of the subset #2 cases in our panel
wereBinet A,whereas70%ofthosefrom Marincevicetal.[18] were
either in advanced clinical stages or no information was provided,
thus preventing any definitive comparison.
In our study, we described a recurrent favorable cytogenetic
profile and the indolent course in subset #4 patients. This finding is
in agreement with data reported by some authors [10,18], but not
by others [17], leaving this aspect still controversial. Finally, we
confirmed that trisomy 12 was correlated with IGHV4-39
stereotyped HCDR3 subsets #8 and #10 [17,20] showing that
Figure 2. TTFT analysis of subset #1. Subset #1 patients were
compared to those positive for del(17)(13p) and del(11)(q23), and those
with UM or M IGHV status.
doi:10.1371/journal.pone.0024313.g002
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expression.
In conclusion, our study indicates that distinct stereotyped
HCDR3 regions of BCR in CLL are characterized by specific
cytogenetic and/or molecular profiles and clinical course. Further
validation in larger and prospective series of patients may help to
better clarify distinct biological and clinical features of specific
stereotyped subsets.
Supporting Information
Figure S1 Predictive value of Binet A, IGHV gene status,
CD38, ZAP-70 and the most common genomic aberra-
tions evaluated by FISH. Cases were subdivided according to
Binet classification (A), CD38 expression (B), FISH (C), IGHV gene
status (D) and ZAP-70 expression (E) before determining TTFT.
(TIF)
Figure S2 (A) IGHV distribution and association with
mutated (M) or unmutated (UM) IGHV configuration.
IGHV bars were ordered according to the total number of patients
belonging to each subset. Among the most represented IGHV genes,
there was a higher prevalence of M configuration in IGHV3-23 (84/
95; 88.4%), of IGHV4-34 (97/108; 89.8%), (73/83; 87.9%) of
IGHV3-7 (73/83; 87.9%) and of IGHV3-30 (49/66; 74.2%) cases
(representing 42% of all M patients); conversely, 91.4% (106/116)
of IGHV1-69patients were UM(representing26.1%of all UMCLL
gene usage). The IGHV3-21 gene was present in only a small
fraction of cases of our panel (34/1126, 3%; 14 UM and 20 M),
confirming its low prevalence in a Mediterranean cohort of CLL
patients. (B) IGHD distribution and association with M and UM
IGHV configuration. IGHD bars were ordered by the total number
of patients belonging to each subset. IGHD gene distribution was
similar to that described for other cohorts. IGHD3-3 was the most
used IGHD gene and it was significantly associated with the UM
configuration (108/133; 81.2%). On the contrary, IGHD3-10 (67/
95; 70.5%), IGHD2-15 (43/49; 87.8%), IGHD1-26 (50/59; 54.7%),
and IGHD3-22 (64/97; 66%) were significantly associated with the
M configuration. (C) IGHJ gene distribution and association with
IGHV mutational status. IGHJ4 and 6 were the most represented
IGHJ gene and they were associated with M (361/498; 72.5%) and
UM (189/353; 53.5%) mutational status, respectively.
(TIF)
Table S1 BCR molecular features of previously de-
scribed subets.
(XLS)
Table S2 Clinical and molecular features of 31 new
putative subsets
(XLS)
Table S3 Distribution of IGHV3-21 in patients from
North and South Italy.
(XLS)
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